Derechos | Equipo Nizkor
Coronavirus vaccine: Russia's Sechenov University successfully completes trials of world's first COVID-19 vaccine
The clinical trials of the world's first coronavirus vaccine on volunteers at Sechenov First Moscow State Medical University has been successfully completed, Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, told Sputnik, adding that the first group of volunteers would be discharged on Wednesday and the second on July 20. The university began clinical trials of the vaccine produced by Russia's Gamalei Institute of Epidemiology and Microbiology on June 18.
"Sechenov University has successfully completed tests on volunteers of the world's first vaccine against coronavirus," Tarasov said. According to Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical and Vector-Borne
Diseases at Sechenov University, the objective of this stage of the study was to show the vaccine's safety for human health, which was successfully done.
"The safety of the vaccine is confirmed. It corresponds to the safety of those vaccines that are currently on the market," Lukashev told Sputnik. The further vaccine development plan is already being determined by the developer's strategy, including the complexity of the epidemiological situation with the virus and the possibility of scaling up production, Lukashev added.
"Sechenov University in a pandemic situation acted not only as an educational institution but also as a scientific and technological research center that is able to participate in the creation of such important and complex products as drugs ... We worked with this vaccine, starting with preclinical studies and protocol development, and clinical trials are currently underway.
[Source: Times of India, Ani, Delhi, 12Jul20]
Bookshop Donate Radio Nizkor
This document has been published on 16jul20 by the Equipo Nizkor and Derechos Human Rights. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.